SPECIAL EDITION: How PhRMA members are combating COVID-19
Although we are still gaining more information about COVID-19, a disease caused by a novel form of the coronavirus, we want to share an update on what our companies are doing to take action.
The biopharmaceutical industry is working around the clock and devoting resources and capabilities to identify and develop new ways to prevent, diagnose and treat this deadly disease.
Additionally, more than 50% of PhRMA members are:
• Researching and developing potential new vaccines and testing possible treatments for those patients currently infected.
• Using new technologies with our extensive experience and knowledge to accelerate development for a treatment.
• Strengthening our manufacturing capacity to meet the demand.
• Collaborating with key stakeholders, like the Centers for Disease Control and Prevention, World Health
Organization, international health organizations and more.
PhRMA is confident in our members’ potential to develop effective COVID-19 vaccines and medicines. Our industry has the advantage of decades of scientific research cultivated from experience with similar viruses, such as MERS, SARS, Ebola and influenza. Additionally, the United States’ unique biopharmaceutical ecosystem encourages collaboration between the government, academia, industry and investors. These and other reasons increase our ability to deliver new treatments and vaccines to patients quickly and affordably.
Developing vaccines and treatments for pandemics is challenging, but our industry is prepared and has an arsenal of new and innovative technologies that aim at finding a safe, affordable and effective solution. While our industry is well-positioned to find an effective vaccine and treatment options and is doing just that, we also continue to collaborate with government agencies, like the NIH and BARDA, to better understand the trajectory of the virus and work collectively to address this public health emergency.
Our companies will do everything we can to beat this virus as quickly and as safely as possible. And we working with governments and insurers to ensure that when new treatments and vaccines are approved they will be available and affordable for patients.
Click here to watch leading biopharmaceutical representatives discuss the industry’s response to COVID-19 and stay updated on PhRMA’s efforts to combat the coronavirus by following www.phrma.org/coronavirus.
